ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.4 | 0.6 | 1.5 |
| Total income | 0.4 | 0.6 | 1.5 |
| Profit before exceptional items & tax | 0.2 | -0.4 | 1.3 |
| Profit before tax | 0.2 | -0.4 | 1.3 |
| Net profit | 0.2 | -0.4 | 1.3 |
| Operating margin | 50.0% | -66.7% | 86.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -84.60% |
|---|---|
| Revenue, year on year | -73.30% |
BSE results filing, NSE: SUNTECHNO. Figures extracted from the filing.
Biogen Pharmachem Industries Ltd: key numbers
- Share price
- ₹0.29
- Market cap
- ₹30.54 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.86 Cr
- P/E (TTM)
- 52.4×Sector 20.8×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biogen Pharmachem Industries Ltd
All →Biogen Pharmachem Industries Q2 FY27 Results: Turns Profitable, Net Profit ₹0.3 Cr
Biogen Pharmachem Industries reported un-audited financial results for the quarter ended September 30, 2026. The company posted a net profit of Rs. 25.73 Lakhs for the period.
- Key figure
- Net profit ₹0.3 Cr
Biogen Pharmachem Industries Board Meeting Date
Biogen Pharmachem Industries Ltd intimated a board meeting on 3 November 2026 to approve unaudited results for Q2 and half year ended 30 September 2026. The filing is a meeting notice only, with no monetary event.
Biogen Pharmachem Industries Capital Structure Change
Rama Shiva Lease Finance disposed of all 4.26 crore Biogen Pharmachem shares in open market. The non-promoter now holds zero stake, fully exiting the company.
Biogen Pharmachem Industries Other Announcement
Biogen Pharmachem Industries Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI Regulation 31(1)(b).
Biogen Pharmachem Industries Annual General Meeting
Biogen Pharmachem Industries Limited held its 31st Annual General Meeting on 29th September 2026. Shareholders approved financial statements, director re-appointment, and the auditor appointment.
Biogen Pharmachem Industries Annual Report
Biogen Pharmachem Industries Limited submitted its 31st Annual Report for the financial year 2025-26. The Annual General Meeting is scheduled for September 29, 2026.